Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction

NeuroImage

Volumn 108, Issue , 2015, Pages 450-459

  Brendel, Matthias ^a   Högenauer, Marcus ^a   Delker, Andreas ^a   Sauerbeck, Julia ^a   Bartenstein, Peter ^a   Seibyl, John ^b   Rominger, Axel ^a   for the Alzheimer's Disease Neuroimaging Initiative, ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b MNI   (United States)

^c NONE

Author keywords

18F AV45 PET; Alzheimer's disease; Partial volume effect correction; Reference region

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; FLUORINE 18; FLUORO AV45 F 18; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR;

AGED; ARTICLE; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL VOLUME EFFECT CORRECTION; POSITRON EMISSION TOMOGRAPHY; PROCESS OPTIMIZATION; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; STANDARD UPTAKE VALUE RATIO; VOLUME OF INTEREST; WHITE MATTER; ALZHEIMER DISEASE; CHEMISTRY; PROCEDURES; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; AMYLOID; ANILINE COMPOUNDS; ETHYLENE GLYCOLS; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; WHITE MATTER;

EID: 84922264328     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2014.11.055     Document Type: Article

References (30)

1. Aanerud J., Borghammer P., Chakravarty M.M., Vang K., Rodell A.B., Jonsdottir K.Y., Moller A., Ashkanian M., Vafaee M.S., Iversen P., Johannsen P., Gjedde A. Brain energy metabolism and blood flow differences in healthy aging. J. Cereb. Blood Flow Metab. 2012, 32:1177-1187.
2. Ashburner J., Friston K.J. Unified segmentation. Neuroimage 2005, 26:839-851.
3. 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J. Nucl. Med. 2012, 53:59-71.
4. Borghammer P., Cumming P., Aanerud J., Forster S., Gjedde A. Subcortical elevation of metabolism in Parkinson's disease-a critical reappraisal in the context of global mean normalization. Neuroimage 2009, 47:1514-1521.
5. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
6. Brendel M., Delker A., Rotzer C., Boning G., Carlsen J., Cyran C., Mille E., Gildehaus F.J., Cumming P., Baumann K., Steiner H., Haass C., Herms J., Bartenstein P., Rominger A. Impact of partial volume effect correction on cerebral beta-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET. Neuroimage 2014, 84:843-853.
7. Clark C.M., Pontecorvo M.J., Beach T.G., Bedell B.J., Coleman R.E., Doraiswamy P.M., Fleisher A.S., Reiman E.M., Sabbagh M.N., Sadowsky C.H., Schneider J.A., Arora A., Carpenter A.P., Flitter M.L., Joshi A.D., Krautkramer M.J., Lu M., Mintun M.A., Skovronsky D.M. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012, 11:669-678.
8. 18F]fluorodeoxyglucose-positron-emission tomography study with partial volume effects correction. AJNR Am. J. Neuroradiol. 2011, 32:560-565.
9. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
10. Dukart J., Perneczky R., Forster S., Barthel H., Diehl-Schmid J., Draganski B., Obrig H., Santarnecchi E., Drzezga A., Fellgiebel A., Frackowiak R., Kurz A., Muller K., Sabri O., Schroeter M.L., Yakushev I. Reference cluster normalization improves detection of frontotemporal lobar degeneration by means of FDG-PET. PLoS One 2013, 8:e55415.
11. Edison P., Hinz R., Ramlackhansingh A., Thomas J., Gelosa G., Archer H.A., Turkheimer F.E., Brooks D.J. Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans?. Neuroimage 2012, 60:1716-1723.
12. Erlandsson K., Buvat I., Pretorius P.H., Thomas B.A., Hutton B.F. A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. Phys. Med. Biol. 2012, 57:R119-R159.
13. Hammers A., Allom R., Koepp M.J., Free S.L., Myers R., Lemieux L., Mitchell T.N., Brooks D.J., Duncan J.S. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum. Brain Mapp. 2003, 19:224-247.
14. Jack C.R., Bernstein M.A., Fox N.C., Thompson P., Alexander G., Harvey D., Borowski B., Britson P.J., Whitwell J.L., Ward C., Dale A.M., Felmlee J.P., Gunter J.L., Hill D.L., Killiany R., Schuff N., Fox-Bosetti S., Lin C., Studholme C., DeCarli C.S., Krueger G., Ward H.A., Metzger G.J., Scott K.T., Mallozzi R., Blezek D., Levy J., Debbins J.P., Fleisher A.S., Albert M., Green R., Bartzokis G., Glover G., Mugler J., Weiner M.W. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J. Magn. Reson. Imaging 2008, 27:685-691.
15. Johnson K.A., Sperling R.A., Gidicsin C.M., Carmasin J.S., Maye J.E., Coleman R.E., Reiman E.M., Sabbagh M.N., Sadowsky C.H., Fleisher A.S., Murali Doraiswamy P., Carpenter A.P., Clark C.M., Joshi A.D., Lu M., Grundman M., Mintun M.A., Pontecorvo M.J., Skovronsky D.M., group, A.A.s Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013, 9:S72-S83.
16. Joshi A.D., Pontecorvo M.J., Clark C.M., Carpenter A.P., Jennings D.L., Sadowsky C.H., Adler L.P., Kovnat K.D., Seibyl J.P., Arora A., Saha K., Burns J.D., Lowrey M.J., Mintun M.A., Skovronsky D.M., Florbetapir F.S.I. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J. Nucl. Med. 2012, 53:378-384.
17. Jovicich J., Czanner S., Greve D., Haley E., van der Kouwe A., Gollub R., Kennedy D., Schmitt F., Brown G., Macfall J., Fischl B., Dale A. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage 2006, 30:436-443.
18. Landau S.M., Thomas B.A., Thurfjell L., Schmidt M., Margolin R., Mintun M., Pontecorvo M., Baker S.L., Jagust W.J. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur. J. Nucl. Med. Mol. Imaging 2014, 41:1398-1407.
19. Lim Y.Y., Ellis K.A., Pietrzak R.H., Ames D., Darby D., Harrington K., Martins R.N., Masters C.L., Rowe C., Savage G., Szoeke C., Villemagne V.L., Maruff P., Group A.R. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 2012, 79:1645-1652.
20. Lim Y.Y., Maruff P., Pietrzak R.H., Ellis K.A., Darby D., Ames D., Harrington K., Martins R.N., Masters C.L., Szoeke C., Savage G., Villemagne V.L., Rowe C.C., Group A.R. Abeta and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimers Dement. 2014, 10:743-751.
21. Rousset O.G., Ma Y., Evans A.C. Correction for partial volume effects in PET: principle and validation. J. Nucl. Med. 1998, 39:904-911.
22. Rousset O.G., Collins D.L., Rahmim A., Wong D.F. Design and implementation of an automated partial volume correction in PET: application to dopamine receptor quantification in the normal human striatum. J. Nucl. Med. 2008, 49:1097-1106.
23. Sled J.G., Zijdenbos A.P., Evans A.C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998, 17:87-97.
24. Thomas B.A., Erlandsson K., Modat M., Thurfjell L., Vandenberghe R., Ourselin S., Hutton B.F. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:1104-1119.
25. 11C-PiB: methodologic considerations. J. Nucl. Med. 2013, 54:1570-1576.
26. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., Ames D., Rowe C.C., Masters C.L. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013, 12:357-367.
27. Weiner M.W., Veitch D.P., Aisen P.S., Beckett L.A., Cairns N.J., Green R.C., Harvey D., Jack C.R., Jagust W., Liu E., Morris J.C., Petersen R.C., Saykin A.J., Schmidt M.E., Shaw L., Shen L., Siuciak J.A., Soares H., Toga A.W., Trojanowski J.Q. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013, 9:e111-e194.
28. 18F]FDDNP PET using subcortical white matter as reference region. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:575-588.
29. Yakushev I., Landvogt C., Buchholz H.G., Fellgiebel A., Hammers A., Scheurich A., Schmidtmann I., Gerhard A., Schreckenberger M., Bartenstein P. Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18. Psychiatry Res. 2008, 164:143-153.
30. Ziegler-Graham K., Brookmeyer R., Johnson E., Arrighi H.M. Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement. 2008, 4:316-323.